Navigation Links
Brown researchers make major signal transduction discovery
Date:10/4/2007

PROVIDENCE, R.I. [Brown University] The chemical process known as acetylation plays a central role in cytokine receptor signal transduction a fundamental biochemical cascade inside cells that controls the activity of antiviral and tumor-suppressing genes.

A team of cell biologists led by Eugene Chin, M.D., a research professor at The Warren Alpert Medical School of Brown University and a staff researcher at Rhode Island Hospital, reports its findings in the journal Cell. Their results are surprising.

Scientists have long known that phosphorylation, an amino acid modifying process in proteins, is critical for switching receptors on and off on the surface of cells. Chin and his team studied how type 1 interferon binds to a receptor complex, known as the IFN-α receptor, on the cell surface to trigger an immune response. Chin and his team found that acetylation, another chemical process that modifies amino acids, plays a central role in activating interferon receptors.

Interferons play a crucial role in the bodys defense against infection and uncontrolled cell growth. Type 1 interferon is widely used to treat hepatitis B and C and cancers such as melanoma and leukemia.

This is a major discovery in the field of signal transduction, Chin said. Tyrosine phosphorylation has so far been considered the major player in signal transduction. But what we discovered challenges this concept. We found another player acetylation in the process.

In their experiments, Chin and his team looked at how cells respond to type 1 interferon, a protein produced in response to a viral infection or other immune trigger. The researchers found that type 1 interferon receptors, which are found in every cell in the body, call up cytoplasmic CREB-binding protein, or CBP, to move up to the cell surface. CPB acetylates these receptors. That, in turn, sparks a biochemical cascade that attracts more proteins to create a complex called ISGF3. To activate this protein complex, Chin found, acetylation is required. Once that occurs, the complex travels to the cell nucleus to switch on anti-viral or tumor-suppressing genes.

The discovery of the acetylation of cytokine receptors marks a milestone in the study of signal transduction, the process of how cells receive and respond to chemical messages.

Many diseases, such as diabetes, cancer and heart disease, occur when signal transduction goes awry. That is why some drugs either inhibit or amplify signaling inside cells by targeting tyrosine phosphorylation. By showing that another chemical process is critical to signal transduction, Chins findings may explain why some anti-cancer or anti-viral drugs do not work for everyone. The findings provide an important new target for therapies that fight cancer and viral infectious diseases.


'/>"/>

Contact: Wendy Lawton
Wendy_Lawton@brown.edu
401-863-1862
Brown University
Source:Eurekalert

Related medicine news :

1. Wholly Ingrained: White or Brown? Food War Going Racist? Get to the Heart of the Matter
2. Louisiana Residents Warned Against Brown Recluse Spiders
3. Scientists Identify "master Switch" for Brown Fat in Mice
4. Researchers urge caution in using ear tube surgery
5. Researchers Scale to assess the Severity of Epilepsy in Kids
6. Researchers identify the early makers of Neonatal Sepsis
7. OHSU Researchers Announce New Discovery
8. Researchers Identify Gene Connected To Bipolar Disorder
9. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
10. Researchers trick Alzheimers Enzyme
11. Researchers find new HIV hiding place
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... It's not always common knowledge whether or not a ... unclear as to whether or not they are contagious, and most people don't know ... So, FindaTopDoc took a look into the matter. , They discovered that the ...
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
Breaking Medicine Technology: